Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. (CYBN) is a clinical-stage biopharmaceutical leader advancing novel psychedelic-based therapies for mental health conditions. This dedicated news hub provides investors and researchers with essential updates on the company's progress in developing innovative treatment solutions.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships that shape Cybin's research pipeline. Our curated collection includes official press releases detailing advancements in deuterated compound research, intellectual property achievements, and collaborative neuroscience initiatives.
Key updates cover FDA designations, preclinical study results, and patent filings that demonstrate Cybin's scientific rigor in psychedelic therapeutics development. The resource serves as a centralized tracking point for material events influencing the company's position in mental health innovation.
Bookmark this page for structured access to verified information about Cybin's therapeutic candidates and operational developments. Check regularly for objective updates on progress within the regulated biopharmaceutical research landscape.
Cybin Inc. (NYSE American:CYBN), a clinical-stage neuropsychiatry company, announces that CEO Doug Drysdale will participate in a Water Tower Research Fireside Chat on May 29, 2025, at 11:00 a.m. ET. The discussion, hosted by Senior Research Analyst Robert Sassoon, will cover several key topics including: the evolution of interventional psychiatry clinics and Cybin's Osmind partnership, updates on the CYB003 Phase 3 program, strategic clinical partnerships, the Thermo Fisher collaboration, upcoming milestones, and insights on FDA developments in psychedelics.
Cybin (NYSE:CYBN) has partnered with Thermo Fisher Scientific for Phase 3 clinical supply and potential commercial manufacturing of CYB003, its deuterated psilocin program for Major Depressive Disorder (MDD) treatment. The manufacturing operations will be based in the U.S., with drug substance production in Florence, South Carolina, and capsule production in Cincinnati, Ohio.
CYB003 received FDA Breakthrough Therapy Designation in March 2024, enabling expedited review and faster development. The program's Phase 2 results showed impressive efficacy with a 100% response rate and 71% remission rate among participants receiving two 16mg doses at 12 months. The company launched PARADIGM™, its multinational Phase 3 program, in November 2024 to evaluate CYB003 in a broader MDD patient population.
Cybin Inc. (NYSE American:CYBN), a clinical-stage neuropsychiatry company, announces its participation in the upcoming Alliance Global Partners Healthcare Company Showcase. CEO Doug Drysdale will engage in a fireside chat during this virtual event on May 21, 2025, at 1:40 p.m. ET. The presentation will be accessible via live webcast, with an archived version available on Cybin's investor relations website under the Events & Presentations section.
Cybin (NYSE:CYBN) has secured a new U.S. patent (12,291,499) for its CYB003 program, which is currently in Phase 3 development for Major Depressive Disorder (MDD). The patent, providing exclusivity until 2041, covers pharmaceutical compositions and oral dosage forms within the company's proprietary deuterated psilocin analog program.
The company's intellectual property portfolio now includes over 80 granted patents and 230+ pending applications. Cybin is actively conducting two Phase 3 studies: the ongoing APPROACH study for CYB003 as an adjunctive treatment for MDD, and the upcoming EMBRACE study, scheduled to begin in mid-2025.
Cybin Inc. (NYSE American:CYBN) announced that CEO Doug Drysdale will participate in the 28th Annual Milken Institute Global Conference, speaking on a panel titled "The Global Landscape and Opportunities for Medical Breakthroughs." The panel discussion will take place on May 5, 2025, at 2:30 p.m. PDT at the Beverly Hilton in Los Angeles.
The conference runs from May 4-7, 2025. Drysdale emphasized the company's role in advancing medical innovation and developing precise treatment regimens. The panel discussion will be available via live webcast and archived on Cybin's investor relations website.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
